MX2020001432A - Anticuerpos que se unen al receptor del factor de crecimiento epidermico (egfr) y tirosina-proteina cinasa met (cmet). - Google Patents

Anticuerpos que se unen al receptor del factor de crecimiento epidermico (egfr) y tirosina-proteina cinasa met (cmet).

Info

Publication number
MX2020001432A
MX2020001432A MX2020001432A MX2020001432A MX2020001432A MX 2020001432 A MX2020001432 A MX 2020001432A MX 2020001432 A MX2020001432 A MX 2020001432A MX 2020001432 A MX2020001432 A MX 2020001432A MX 2020001432 A MX2020001432 A MX 2020001432A
Authority
MX
Mexico
Prior art keywords
antibody
bind
variable domain
cmet
egfr
Prior art date
Application number
MX2020001432A
Other languages
English (en)
Inventor
Throsby Mark
Anna Wilhelmina Geuijen Cecilia
Adriaan De Kruif Cornelis
Logtenberg Ton
Cornelis Roovers Robertus
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MX2020001432A publication Critical patent/MX2020001432A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invención se refiere a anticuerpos biespecíficos que comprenden un primer dominio variable que puede unirse a una parte extracelular del receptor del factor de crecimiento epidérmico (EGFR) y un segundo dominio variable que puede unirse a una parte extracelular del Proto-Oncogén de MET, Receptor de Tirosina Cinasa (cMET). El anticuerpo puede comprender una cadena ligera común. Puede ser un anticuerpo humano. El anticuerpo puede ser un anticuerpo de longitud completa. En algunas modalidades el anticuerpo biespecífico es un anticuerpo de formato IgG1 que tiene una estequiometria anti-cMET, anti-EGFR de 1:1. En algunas modalidades, el anticuerpo tiene un dominio variable que puede unirse al EGFR y un dominio variable que puede unirse a cMET.
MX2020001432A 2017-08-09 2018-08-09 Anticuerpos que se unen al receptor del factor de crecimiento epidermico (egfr) y tirosina-proteina cinasa met (cmet). MX2020001432A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17185572 2017-08-09
PCT/NL2018/050537 WO2019031965A1 (en) 2017-08-09 2018-08-09 ANTIBODIES THAT BIND EGFR AND CMET

Publications (1)

Publication Number Publication Date
MX2020001432A true MX2020001432A (es) 2020-03-20

Family

ID=59579503

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001432A MX2020001432A (es) 2017-08-09 2018-08-09 Anticuerpos que se unen al receptor del factor de crecimiento epidermico (egfr) y tirosina-proteina cinasa met (cmet).

Country Status (16)

Country Link
US (1) US11773170B2 (es)
EP (1) EP3665198A1 (es)
JP (2) JP2020530028A (es)
KR (1) KR20200042485A (es)
CN (1) CN111094351A (es)
AU (2) AU2018312816B2 (es)
BR (1) BR112020002695A2 (es)
CA (1) CA3072404A1 (es)
EA (1) EA202090215A1 (es)
IL (1) IL272461A (es)
MA (1) MA49846A (es)
MX (1) MX2020001432A (es)
PH (1) PH12020550055A1 (es)
SG (1) SG11202001050PA (es)
TW (1) TW201910354A (es)
WO (1) WO2019031965A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3912998A3 (en) 2015-10-23 2022-02-23 Merus N.V. Binding molecules that inhibit cancer growth
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
JP2020511993A (ja) 2017-03-31 2020-04-23 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ−２及びＥｒｂＢ３結合二重特異性抗体
BR112020019795A2 (pt) * 2018-03-30 2021-01-05 Merus N.V. Anticorpo multivalente
WO2020168024A1 (en) * 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
MX2021013646A (es) 2019-05-09 2022-01-31 Merus Nv Dominios variantes para las proteínas multimerizantes y su separación.
CA3146933A1 (en) 2019-09-16 2021-03-25 Marcus KELLY Radiolabeled met binding proteins for immuno-pet imaging
CN112898427B (zh) * 2019-12-03 2023-06-30 同济大学苏州研究院 一种抗c-Met单臂抗体及其制备方法和应用
AU2022309554A1 (en) 2021-07-14 2024-02-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereof
WO2023172133A1 (en) 2022-03-07 2023-09-14 Merus N.V. Combination therapy including antibodies that bind egfr and cmet
TW202346353A (zh) 2022-03-07 2023-12-01 荷蘭商美勒斯公司 利用結合EGFR及cMET之抗體的治療
WO2024002235A1 (en) * 2022-06-29 2024-01-04 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-egfr/met antibodies and uses thereof

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
FI884924A (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
JP3502093B2 (ja) 1991-07-15 2004-03-02 ザ・ウエルカム・ファウンデーション・リミテッド 抗体の製造
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE29706518U1 (de) 1997-04-11 1997-05-22 Missel Gmbh & Co E Trägersystem für Bade-, Dusch- oder Whirlwannen
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
SI1161548T2 (sl) 1999-04-15 2010-02-26 Crucell Holland Bv Priprava rekombinantnega proteina v humani celici z uporabo sekvenc, ki kodirajo adenovirusni E1 protein
DE29915950U1 (de) 1999-09-10 1999-12-30 Cmw Automation Gmbh Vorrichtung zum Elektrolytbefüllen der Zellen eines Akkumulators
US20070111201A1 (en) 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
ATE466942T1 (de) 2001-07-04 2010-05-15 Chromagenics Bv Dns-sequenzen mit anti-repressor aktivität
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20050130224A1 (en) 2002-05-31 2005-06-16 Celestar Lexico- Sciences, Inc. Interaction predicting device
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
AU2004203727C1 (en) 2003-01-07 2008-08-21 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
BRPI0510716A (pt) 2004-05-05 2007-11-20 Merrimack Pharmaceuticals Inc uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
EP1753783B1 (en) 2004-06-03 2014-08-06 Novimmune SA Anti-cd3 antibodies and methods of use thereof
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008531557A (ja) 2005-02-23 2008-08-14 メリマック ファーマシューティカルズ インコーポレーティッド 生物活性を調節するための二重特異性結合剤
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
US8580263B2 (en) 2006-11-21 2013-11-12 The Regents Of The University Of California Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
NZ614857A (en) 2007-03-29 2015-04-24 Genmab As Bispecific antibodies and methods for production thereof
WO2008119566A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
US7705103B2 (en) 2007-06-22 2010-04-27 3M Innovative Properties Company Polydiorganosiloxane polyoxamide copolymers
EP3009148B1 (en) 2007-07-02 2018-08-22 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
WO2009051974A1 (en) 2007-10-17 2009-04-23 Nuvelo, Inc. Antibodes to cll-1
EP2235536A4 (en) 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2 DIAGNOSTIC METHODS
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
ES2774337T3 (es) 2008-01-07 2020-07-20 Amgen Inc Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
CA2715043C (en) 2008-02-05 2021-02-16 Zymeworks Inc. Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
MX2010014542A (es) 2008-06-27 2011-04-05 Merus B V Mamiferos no humanos los cuales producen anticuerpos.
US8663640B2 (en) 2008-08-29 2014-03-04 Symphogen A/S Methods using recombinant anti-epidermal growth factor receptor antibody compositions
KR20110112301A (ko) 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
JP5746051B2 (ja) 2009-01-15 2015-07-08 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ−３の測定による患者の反応を判定する方法
CN104262483A (zh) 2009-01-26 2015-01-07 根马布股份公司 用于生成抗体混合物的方法
MA33198B1 (fr) 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
CN102471378B (zh) 2009-06-26 2014-04-02 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
MX336091B (es) 2009-08-21 2016-01-08 Merrimack Pharmaceuticals Inc Anticuerpos contra el extodominio de erbb3 y usos de los mismos.
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2496598B1 (en) 2009-11-04 2017-08-02 Affibody AB Her3 binding polypeptides
WO2011097603A1 (en) 2010-02-08 2011-08-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
CA2808482C (en) 2010-08-16 2021-10-26 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
CN103080134B (zh) 2010-08-20 2015-11-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
JP2014511383A (ja) 2011-02-24 2014-05-15 メリマック ファーマシューティカルズ インコーポレーティッド 抗ＥｒｂＢ３剤を含む併用療法
SG192844A1 (en) 2011-03-11 2013-09-30 Merrimack Pharmaceuticals Inc Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
JP2014509593A (ja) 2011-03-15 2014-04-21 メリマック ファーマシューティカルズ インコーポレーティッド ＥｒｂＢ経路阻害剤に対する耐性の克服
NZ608724A (en) 2011-03-25 2015-12-24 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
DK2707391T3 (en) 2011-05-13 2018-02-05 Gamamabs Pharma ANTIBODIES AGAINST HER3
WO2012176779A1 (ja) 2011-06-20 2012-12-27 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
AU2012284254B2 (en) 2011-07-15 2015-07-09 Oncomed Pharmaceuticals, Inc. RSPO binding agents and uses thereof
US9567827B2 (en) 2013-07-15 2017-02-14 Downhole Technology, Llc Downhole tool and method of use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
IN2014CN03042A (es) 2011-09-30 2015-07-03 Regeneron Pharma
EP3608340A1 (en) 2011-11-23 2020-02-12 Medlmmune, LLC Binding molecules specific for her3 and uses thereof
CA2857939A1 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
US20130251703A1 (en) 2011-12-05 2013-09-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
CN102448183A (zh) 2012-01-18 2012-05-09 大唐移动通信设备有限公司 一种Uu接口重配置方法及设备
JP6231503B2 (ja) 2012-03-09 2017-11-15 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ ｐＨセンサー
AU2013240261A1 (en) 2012-03-27 2014-09-18 Genentech, Inc. Diagnosis and treatments relating to HER3 inhibitors
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
EA035344B1 (ru) 2012-04-20 2020-05-29 Мерюс Н.В. Способ получения двух антител из одной клетки-хозяина
TWI641619B (zh) * 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
US10093740B2 (en) 2012-10-15 2018-10-09 Universitat Zurich Bispecific HER2 ligands for cancer therapy
SI3447069T1 (sl) * 2012-11-21 2021-02-26 Janssen Biotech, Inc. Bispecifična protitelesa EGFR/C-MET
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
MX2015011518A (es) 2013-03-14 2016-02-03 Oncomed Pharm Inc Agentes de enlace de met y usos de los mismos.
EP2981828A1 (en) 2013-04-05 2016-02-10 Laboratory Corporation of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
CA2910945A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
WO2014197854A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
WO2015018918A1 (en) 2013-08-07 2015-02-12 Universität Zu Köln Novel nrg1 fusion genes in cancer
US9551208B2 (en) 2013-08-26 2017-01-24 Halliburton Energy Services, Inc. Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation
US10519247B2 (en) 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
JP6771385B2 (ja) * 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
SG10201913289TA (en) 2014-02-28 2020-02-27 Merus Nv Antibody that binds erbb-2 and erbb-3
SG11201606979TA (en) 2014-03-11 2016-09-29 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
JP6614582B2 (ja) 2014-04-04 2019-12-04 バイオノミクス インコーポレイテッド Ｌｇｒ５に結合するヒト化抗体
WO2016077734A2 (en) 2014-11-14 2016-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nk cells with an increased antibody-dependent cellular toxicity (adcc) against tumors
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
CA2991880A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
EP3912998A3 (en) * 2015-10-23 2022-02-23 Merus N.V. Binding molecules that inhibit cancer growth
JP2020511993A (ja) 2017-03-31 2020-04-23 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ−２及びＥｒｂＢ３結合二重特異性抗体

Also Published As

Publication number Publication date
SG11202001050PA (en) 2020-03-30
AU2021202874A1 (en) 2021-06-03
PH12020550055A1 (en) 2020-10-19
JP2024029049A (ja) 2024-03-05
JP2020530028A (ja) 2020-10-15
EP3665198A1 (en) 2020-06-17
AU2018312816B2 (en) 2021-05-27
IL272461A (en) 2020-03-31
MA49846A (fr) 2020-06-17
BR112020002695A2 (pt) 2020-08-25
US20200247892A1 (en) 2020-08-06
US11773170B2 (en) 2023-10-03
EA202090215A1 (ru) 2020-07-01
WO2019031965A1 (en) 2019-02-14
CA3072404A1 (en) 2019-02-14
AU2018312816A1 (en) 2020-02-27
CN111094351A (zh) 2020-05-01
KR20200042485A (ko) 2020-04-23
TW201910354A (zh) 2019-03-16

Similar Documents

Publication Publication Date Title
PH12020550055A1 (en) Antibodies that bind egfr and cmet
MX2020006408A (es) Moléculas de unión al antígeno biespecíficas.
AU2018275359A1 (en) Antibodies specific for FLT3 and their uses
JOP20210304A1 (ar) علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
EA201990171A1 (ru) Биспецифичное антитело против egfr и против cd3 и его применения
PH12016502064A1 (en) Human antibodies to middle east respiratory syndrome-coronavirus spike protein
NZ732628A (en) Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof
EP3991748A3 (en) Anti-sortilin antibodies and methods of use thereof
MY185813A (en) Factor xi antibodies and methods of use
NZ762843A (en) Anti-egfr antibodies and antibody drug conjugates
NZ604003A (en) Monoclonal antibodies against her2
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
SG10201801219VA (en) Anti-HER2 Antibodies
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
WO2015173756A3 (en) Bispecific antibodies with engineered ch1-cl interfaces
WO2013164689A3 (en) Humanized pan-her antibody compositions
PH12015501118A1 (en) Bispecific egfr/c-met antibodies
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EA201590085A1 (ru) Антитела анти-egfr и их применение
MX2012011718A (es) Anticuerpos anti-erbb3.
MX2016003256A (es) Anticuerpos modificados del receptor de factor de crecimiento anti-epidermico y metodos de uso de los mismos.
UA110049C2 (uk) ЛІКУВАННЯ ОСТЕОАРТРИТУ ІМУНОГЛОБУЛІНОВИМ ЗВ'ЯЗУВАЛЬНИМ БІЛКОМ З ПОДВІЙНИМ ВАРІАБЕЛЬНИМ ДОМЕНОМ, ЩО ЗВ'ЯЗУЄ IL-1α І IL-1β
WO2015050959A8 (en) Anti-kit antibodies and methods of use thereof
NZ631098A (en) Anti-hepcidin antibodies and uses thereof